Serum lactic dehydrogenase and its isoenzymes in patients with ovarian dysgerminoma

Yoshimura, Toshihiro; Takemori, Koichi; Okazaki, Taichiro; Suzuki, Akira

doi:10.1016/0020-7292(88)90131-2

Cited by 10 publications

(7 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…It has been suggested that serum LDH levels and their isoenzyme pattern are useful tumor markers for diagnosis and post-therapy surveillance. 21 We therefore agree with the previous data 5, 22 that LDH has only a limited clinical use.…”

Section: Discussionsupporting

confidence: 93%

Bilateral ovarian gonadoblastoma with coexisting dysgerminoma in a girl with 46, XX karyotype

Yılmaz¹,

Güngör²,

Bayramoǧlu

et al. 2010

J of Obstet and Gynaecol

View full text Add to dashboard Cite

Gonadoblastoma is a rare gonadal tumor with tumor cells arranged in nests surrounded by ovarian stroma containing Leydig or lutein-type cells. In 50% of the cases, there is an overgrowth of germ cells with progression to dysgerminoma. A case of gonadoblastoma with coexisting dysgerminoma developing in both ovaries of a 20-year-old girl who had increased abdominal girth is presented here. A pelvic mass measuring 20 x 14 cm was detected by pelvic ultrasonography. Bilateral salphingo-oophorectomy was performed. The histopathological report revealed bilateral gonadoblastoma with coexisting dysgerminoma. After surgery the patient received radiation and chemotherapy (BEP: bleomycin, etoposide, cisplatin) and was started on hormone replacement therapy. Five years and eight months after treatment, the patient is well and free of recurrence.

show abstract

Section: Discussionsupporting

confidence: 93%

Bilateral ovarian gonadoblastoma with coexisting dysgerminoma in a girl with 46, XX karyotype

Yılmaz¹,

Güngör²,

Bayramoǧlu

et al. 2010

J of Obstet and Gynaecol

View full text Add to dashboard Cite

show abstract

“…The reported incidence is 0.42 per 1000 pregnancies mainly borderline tumors followed by epithelial tumors [14]. However, diagnosis of ovarian mass was late at 22 weeks of pregnancy as the mass may mimic luteoma of pregnancy and corpus luteum hematoma .The diagnosis was supported by elevated LDH which agreed with other authors [15]. To the best of our knowledge, no published studies to report the association between ovarian stimulating drugs and malignant germ-cell tumors in women with PCOS.…”

Section: Discussionsupporting

confidence: 81%

Malignant Ovarian Dysgerminoma Following Ovulation Induction in Patients with Polycystic Ovarian Syndrome: A Literature Review and Two Case Reports

Said¹,

Zalata²,

El-lakkany³

et al. 2020

COR

View full text Add to dashboard Cite

Background: The relation of ovarian induction drugs to development of ovarian cancer is still unclear. Polycystic ovary syndrome (PCOS) is a complex endocrine disorder that has been reported as a risk factor for ovarian cancer in some studies. Case presentation: We report two cases with polycystic ovarian syndrome who developed a malignant ovarian dysgerminoma following use of ovulation induction drugs. One of them was diagnosed during fifth month of pregnancy by intracytoplasmic injection (ICSI). Both cases were treated with conservative surgery. Conclusion: We reported 2 cases of ovarian dysgerminoma in patients with PCOS following ovarian stimulation. A large multicenter observational study is recommended to investigate a possible association.

show abstract

“…LDH was reported to be raised in malignant primary [17][18][19] and secondary [19] ovarian tumors, with no difference with regards to histological subtypes [18][19]. High LDH levels have been associated with ovarian and extragonadal dysgerminomas [20][21][22][23]. However, older studies did not report a significant association between LDH and ovarian tumors [24].…”

Section: Markermentioning

confidence: 99%

Relationship between Serum Tumor Markers, CA-125, CEA, CA19-9, LDH, and βHCG with Histopathology and Age in Women with Ovarian Tumors

Bagde¹,

Bagde²,

Lone

2020

Asian Pac J Cancer Biol

View full text Add to dashboard Cite

Introduction: Ovarian tumors pose a diagnostic predicament as it is difficult to differentiate benign from malignant without a histopathology report. Appropriate tumor markers may serve as diagnostic aid to better decision making in the management of these cases. We attempted to determine the relationship between age, serum markers, and histopathological sub types of ovarian tumors to help distinguish benign from malignant tumors.Methods: A retrospective cross sectional study of all cases with ovarian tumors that had available histopathology reports and tumor marker levels was done at a single centre. Variables examined were age, histopathology report and serum tumor markers CA-125, CEA, CA19-9, LDH, and βHCG. Results: Histopathological analysis revealed 26% teratomas, 28% cystadenomas, 14% corpus luteal cysts, 26% carcinomas and 6% endometriomas. CA-125 was the only marker that was significantly raised in malignant versus benign tumors (p=0.008) and increased with increasing age. All women with raised CEA reports had teratomas, and none with cancers had a raised CEA. CA19-9, LDH and βHCG were not significantly different in benign versus malignant tumors.Conclusions: CA-125 may be used as an adjuvant diagnostic tool for ovarian cancer in older women. The role of CEA as a marker for teratomas needs further evaluation.

show abstract

Serum lactic dehydrogenase and its isoenzymes in patients with ovarian dysgerminoma

Cited by 10 publications

References 15 publications

Bilateral ovarian gonadoblastoma with coexisting dysgerminoma in a girl with 46, XX karyotype

Bilateral ovarian gonadoblastoma with coexisting dysgerminoma in a girl with 46, XX karyotype

Malignant Ovarian Dysgerminoma Following Ovulation Induction in Patients with Polycystic Ovarian Syndrome: A Literature Review and Two Case Reports

Relationship between Serum Tumor Markers, CA-125, CEA, CA19-9, LDH, and βHCG with Histopathology and Age in Women with Ovarian Tumors

Contact Info

Product

Resources

About